KDventures AB

KDventures AB, formerly known as Karolinska Development AB, is a Nordic life sciences investment company headquartered in Solna, Sweden. Established in 2003, its core mission is to identify breakthrough medical innovations, primarily originating from the Karolinska Institutet and other leading Nordic universities and research institutes, and to invest in the creation and growth of companies that advance these assets into commercial products. The company aims to make a significant difference in patients' lives while delivering attractive returns to shareholders.

The company's strategy involves building portfolio companies around leading scientists, supported by experienced management teams and co-funded by specialist international investors. KDventures AB maintains a portfolio of companies targeting opportunities in innovative treatments for life-threatening or serious debilitating diseases, with investment areas spanning oncology, rare diseases, infectious diseases, digital health, and various biotechnological and medical research fields.

In a significant corporate development, Karolinska Development AB officially changed its name to KDventures AB on January 8, 2026, following approval at an Extraordinary General Meeting. This change followed a resolved rights issue of approximately SEK 203 million in December 2025, approved in January 2026, intended to finance ongoing and new investments, as well as general corporate purposes. Viktor Drvota serves as the CEO, leading the company's entrepreneurial team of investment professionals.